StockData
Viatris Inc logo

Viatris Inc

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/303% below fair value
$19.63−0.25 (-1.26%)

Close on Nov 20, 2026Market cap $22.55BP/E –Yield 2.45%

Viatris Contingent Consideration — Current Portion by Quarter

Contingent Consideration — Current Portion ($M)

Viatris Contingent Consideration — Current Portion: $18.5M in Q3 2026, down 49.9% from a year earlier. That is the lowest of the 11 quarters on record here.

Latest, Q3 2026
18.5
Period ended Sep 30, 2026
Change on a year earlier
-49.9%
36.9 in Q3 2025
History
11 quarters
Since Q4 2022
Sources
9
Documents cited below

Where the Q3 2026 figure comes from

Source: SEC Form 10-Q (2026-11-05) ↗

Reported in SEC Form 10-Q / 10-K Balance Sheet Notes.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedContingent Consideration — Current Portion ($M)Year on yearSource
Q3 2026Sep 30, 202618.5-49.9%SEC Form 10-Q (2026-11-05) ↗
Q2 2026Jun 30, 202618.9-49.1%SEC Form 10-Q (2026-08-06) ↗
Q1 2026Mar 31, 202627.7-38.0%SEC Form 10-Q (2026-05-07) ↗
Q4 2025Dec 31, 202528.5-52.1%SEC Form 10-Q (2026-11-05) ↗
Q3 2025Sep 30, 202536.9-25.9%SEC Form 10-Q (2025-11-06) ↗
Q2 2025Jun 30, 202537.1–SEC Form 10-Q (2025-08-07) ↗
Q1 2025Mar 31, 202544.7–SEC Form 10-Q (2025-05-08) ↗
Q4 2024Dec 31, 202459.5-21.8%SEC Form 10-K (2026-02-26) ↗
Q3 2024Sep 30, 202449.8–SEC Form 10-Q (2024-11-07) ↗
Q4 2023Dec 31, 202376.1+18.2%SEC Form 10-K (2026-02-26) ↗
Q4 2022Dec 31, 202264.4–SEC Form 10-K (2025-02-27) ↗

Cite this data

StockData. (2026). Viatris Contingent Consideration — Current Portion ($M), quarterly Q4 2022–Q3 2026 [Data set]. Compiled from Viatris SEC filings and investor materials. https://stockdatahq.com/stocks/vtrs/kpis/cc-liab-current

See every metric in the Viatris KPI table. Data updated Nov 16, 2026.

See a number that looks wrong?